Insights

Innovative Product Pipeline Cyclopharm’s flagship product Technegas offers advanced lung ventilation imaging, with additional indications for respiratory conditions such as COPD and Asthma, presenting opportunities to expand sales into hospitals and specialty clinics focusing on respiratory diagnostics.

Market Expansion Potential The upcoming launch of Ultralute, designed to improve radiopharmaceutical production efficiency, could attract pharmaceutical and radiopharmacy sectors seeking innovative solutions to enhance their manufacturing processes.

Healthcare Industry Focus Cyclopharm operates within the nuclear medicine segment, catering to a highly specialized healthcare market with increasing demand for non-invasive, functional imaging solutions, aligning with hospitals, imaging centers, and research institutions.

Strategic Collaborations Potential exists for partnerships with large-scale health technology providers such as GE Healthcare or Siemens Healthineers, to integrate Cyclopharm’s products into broader diagnostic workflows and distribution channels globally.

Technological Edge Leveraging advanced manufacturing techniques and proprietary tech like Technegas and Ultralute, Cyclopharm is positioned to attract clients seeking cutting-edge nuclear medicine solutions, especially in markets with growing demand for precise radiopharmaceuticals.

Cyclopharm Tech Stack

Cyclopharm uses 7 technology products and services including WordPress, Google Fonts API, Modernizr, and more. Explore Cyclopharm's tech stack below.

  • WordPress
    Content Management System
  • Google Fonts API
    Font Scripts
  • Modernizr
    Javascript Libraries
  • jQuery
    Javascript Libraries
  • PHP
    Programming Languages
  • ZURB Foundation
    UI Frameworks
  • Google Analytics
    Web Analytics

Media & News

Cyclopharm's Email Address Formats

Cyclopharm uses at least 1 format(s):
Cyclopharm Email FormatsExamplePercentage
FLast@cyclopharm.com.auJDoe@cyclopharm.com.au
47%
First.Last@cyclopharm.com.auJohn.Doe@cyclopharm.com.au
3%
FLast@cyclopharm.com.auJDoe@cyclopharm.com.au
47%
First.Last@cyclopharm.com.auJohn.Doe@cyclopharm.com.au
3%

Frequently Asked Questions

Where is Cyclopharm's headquarters located?

Minus sign iconPlus sign icon
Cyclopharm's main headquarters is located at 1 The Crescent Unit 1 Kingsgrove, NSW 2208 AU. The company has employees across 2 continents, including OceaniaAfrica.

What is Cyclopharm's stock symbol?

Minus sign iconPlus sign icon
Cyclopharm is a publicly traded company; the company's stock symbol is CYC.AX.

What is Cyclopharm's official website and social media links?

Minus sign iconPlus sign icon
Cyclopharm's official website is cyclopharm.com.au and has social profiles on LinkedIn.

What is Cyclopharm's NAICS code?

Minus sign iconPlus sign icon
Cyclopharm's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does Cyclopharm have currently?

Minus sign iconPlus sign icon
As of June 2025, Cyclopharm has approximately 17 employees across 2 continents, including OceaniaAfrica. Key team members include Chief Financial Officer: J. S.Managing Director & Ceo: J. M.Non Executive Board Member: K. B.. Explore Cyclopharm's employee directory with LeadIQ.

What industry does Cyclopharm belong to?

Minus sign iconPlus sign icon
Cyclopharm operates in the Medical Equipment Manufacturing industry.

What technology does Cyclopharm use?

Minus sign iconPlus sign icon
Cyclopharm's tech stack includes WordPressGoogle Fonts APIModernizrjQueryPHPZURB FoundationGoogle Analytics.

What is Cyclopharm's email format?

Minus sign iconPlus sign icon
Cyclopharm's email format typically follows the pattern of FLast@cyclopharm.com.au. Find more Cyclopharm email formats with LeadIQ.

When was Cyclopharm founded?

Minus sign iconPlus sign icon
Cyclopharm was founded in 1986.

Cyclopharm

Medical Equipment ManufacturingNew South Wales, Australia11-50 Employees

Cyclopharm is an Australian ASX listed medical device company primarily involved in the field of nuclear medicine.
Technegas, Cyclopharm’s foundation product is a lung ventilation imaging agent, is a structured ultra-fine dispersion of radioactive labeled carbon. Technegas is produced by drying Technetium-99m, (the most commonly used isotope in nuclear medicine imaging), in a carbon crucible then heating the isotope for a few seconds at around 2,700oC in a Technegas Generator.  The resultant gas-like substance is inhaled by the patient (referred to as lung ventilation) via our consumable product known as a Patient Administration Set (PAS).
The inhaled Technegas particles enables multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for  superior functional ventilation imaging. Technegas is best known for its use in diagnosing Pulmonary Embolism (PE); however, Technegas is now being investigated for additional indications to include the diagnosis and management of COPD, Asthma, CTEPH and the effectiveness of lung reduction interventions
Ultralute, a new product developed by Cyclopharm will be released to the market later in 2016. This first in class, proprietary technology is designed to improve the efficiency, productivity and health care economics in the production of radiopharmaceuticals.

Section iconCompany Overview

Headquarters
1 The Crescent Unit 1 Kingsgrove, NSW 2208 AU
Stock Symbol
CYC.AX
NAICS Code
3391 - Medical Equipment and Supplies Manufacturing
Founded
1986
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $1M

    Cyclopharm's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $1M

    Cyclopharm's revenue is estimated to be in the range of $1M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.